|
Q2 FY2026
As of Jun 27, 2026
|
Q1 FY2026
As of Mar 28, 2026
|
Q4 FY2025
As of Dec 27, 2025
|
Q3 FY2025
As of Sep 27, 2025
|
Q2 FY2025
As of Jun 28, 2025
|
Q1 FY2025
As of Mar 29, 2025
|
Q4 FY2024
As of Dec 28, 2024
|
Q3 FY2024
As of Sep 28, 2024
|
Q2 FY2024
As of Jun 29, 2024
|
Q1 FY2024
As of Mar 30, 2024
|
Q4 FY2023
As of Dec 30, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jul 1, 2023
|
Q1 FY2023
As of Apr 1, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 24, 2022
|
Q2 FY2022
As of Jun 25, 2022
|
Q1 FY2022
As of Mar 26, 2022
|
Q4 FY2021
As of Dec 25, 2021
|
Q3 FY2021
As of Sep 25, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Marketable securities, at fair value | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable, net of allowance of $19,300 and $19,000 at June 27, 2026 and December 27, 2025, respectively | ||||||||||||||||||||
| Contract assets | ||||||||||||||||||||
| Grant income receivable | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Prepaid taxes | ||||||||||||||||||||
| Other receivable, at fair value | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Equity method investment, at fair value | ||||||||||||||||||||
| Equity investments | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued payroll and expenses | ||||||||||||||||||||
| Accrued warranty | ||||||||||||||||||||
| Contract liabilities | ||||||||||||||||||||
| Deferred grant income | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Accrued post-retirement benefits | ||||||||||||||||||||
| Other accrued liabilities | ||||||||||||||||||||
| Customer deposits | ||||||||||||||||||||
| Accrued legal expenses | ||||||||||||||||||||
| Deferred tax liabilities | ||||||||||||||||||||
| Accrued litigation damages | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Non-current contract liabilities, and asset retirement obligations | ||||||||||||||||||||
| Operating lease liabilities, net of current portion | ||||||||||||||||||||
| Accrued post-retirement benefits, net of current portion | ||||||||||||||||||||
| Other long-term liabilities, net of current portion | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Series A redeemable convertible preferred stock, par value $0.01, stated value $7,000 per share; 3,000 shares authorized, no shares issued and outstanding as of June 27, 2026 and 1,000 shares issued and outstanding at December 27, 2025; aggregate liquidation preference of $7,000,000 as of December 27, 2025 | ||||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||||
| Common stock, par value $0.01; 275,000,000 shares authorized as of June 27, 2026 and December 27, 2025, 186,974,903 issued as of June 27, 2026 and 183,015,207 issued as of December 27, 2025, and 180,618,566 outstanding at June 27, 2026 and 176,903,857 at December 27, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Treasury stock 1,102,289 shares at June 27, 2026 and 771,500 shares at December 27, 2025, at cost | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities, redeemable convertible preferred stock, and stockholders’ equity | ||||||||||||||||||||
Loading...
